Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 498 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tarceva (Erlotinib hydrochloride) Clear all
Completed Phase 2 Interventional Results available

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

NCT00709826
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions
gemcitabine, placebo, Erlotinib, apricoxib
Drug
Lead sponsor
Tragara Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
39
States / cities
Tucson, Arizona • Bakersfield, California • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer

NCT00570232
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

NCT00281866
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

NCT00881166
View directory record Official record
Conditions
Malignant Disease
Interventions
MP-470 + topotecan, MP-470 + docetaxel, MP-470 + erlotinib, MP-470 + paclitaxel/carboplatin, MP-470 + carboplatin/etoposide
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Scottsdale, Arizona • Santa Monica, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

NCT00410059
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck

NCT01116336
View directory record Official record
Conditions
Cancer of Head and Neck, Neoplasms, Head and Neck
Interventions
Erlotinib, Green Tea Polyphenon E
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

NCT00276744
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, capecitabine, docetaxel, Erlotinib, Gemcitabine, Irinotecan, mitomycin C, rapamycin, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

NCT01471964
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
Interventions
MLN8237 and Erlotinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

NCT03076164
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV, Recurrent Lung Adenocarcinoma, Recurrent Lung Cancer
Interventions
Trametinib, Erlotinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 14, 2026, 10:45 PM EDT
Suspended Phase 2 Interventional

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

NCT00536770
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
placebo + gemcitabine + erlotinib, Placebo + gemcitabine, calcitriol + gemcitabine, calcitriol + gemcitabine + erlotinib
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

NCT02273362
View directory record Official record
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
6
States / cities
Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

NCT02057380
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
linsitinib, erlotinib, paclitaxel, Bortezomib, Dexamethasone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 14, 2026, 10:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

NCT00977470
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Erlotinib, Hydroxychloroquine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
4
States / cities
Stanford, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 1Phase 2 Interventional

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

NCT01455389
View directory record Official record
Conditions
Lung Cancer
Interventions
DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine
Drug
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

NCT02004262
View directory record Official record
Conditions
2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Interventions
GVAX Pancreas Vaccine, CRS-207, Chemotherapy, cyclophosphamide
Biological · Drug
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

NCT00826449
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
Dasatinib, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer

NCT00365391
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
bevacizumab, erlotinib hydrochloride
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

NCT00278148
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, Erlotinib, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Nathan Pennell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NCT01248247
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, AZD6244, MK-2206, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 14, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

NCT03213626
View directory record Official record
Conditions
Pancreatic Adenocarcinoma Metastatic
Interventions
Cabozantinib 40 MG, Erlotinib 100Mg Tab
Drug
Lead sponsor
Patrick Joseph Loehrer Sr.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT03403049
View directory record Official record
Conditions
Pancreatic Cancer, Cancer
Interventions
Carbon Ion, Gemcitabine + Cisplatin, Gemcitabine + Capecitabine, Gemcitabine + Erlotinib, Gemcitabine, Photon
Radiation · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

NCT00408499
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, erlotinib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

NCT00708448
View directory record Official record
Conditions
Cancer, Non Small Cell Lung Cancer
Interventions
PET Imaging, Erlotinib, Bevacizumab
Radiation · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 14, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

NCT00095225
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local
Interventions
Avastin (bevacizumab), Tarceva (erlotinib HCl)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
48
States / cities
Bakersfield, California • Concord, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 14, 2026, 10:45 PM EDT